Phase I & II trials In June 2020, Phase I trial were launched to assess safety, reactogenicity, and immunogenicity at multiple dose levels with 151 participants in Perth, Australia using 2 separate adjuvants, AS03 and CpG/Alum. In results published in The Lancet,<unk>  resulted in a strong immune responses against COVID-19, with high viral neutralizing activity (antibody geometric mean titres were 1567–4452 with AS03 and 174–2440 with CpG/Alum). Both adjuvanted vaccines were well tolerated and determined to be suitable for further clinical development. In August 2021, a Phase II trial will launch to assess immunogenicity and safety with 800 participants in China. Phase II/III trials In March 2021, a larger combined-Phase II/III trial was launched to evaluate efficacy, immunogenicity, reactogenicity, and safety of the CpG/Alum adjuvated<unk>  vaccine. In July 2021, enrollment in the Phase II/III trials was completed with 45% of the 29,000 participants in Asia, 45% in Latin America and the rest in Europe and Africa. Efficacy against variants In September 2021, results published in The Journal of Infectious Diseases showed<unk>  induced antibodies responses up to 184 days in the Phase I trial. Additionally, the vaccine produced neutralizing antibodies against three of the most common variants of concern; Alpha, Beta, and Gamma. In September 2021, the COVID-19 vaccine candidate showed 79% efficacy against the delta variant in its Phase II/III trials.
SCB-2019
HPTN 052
TIME-ITEM
DCAP-BTLS
SWAP-200
STAR*D
COMLEX-USA
WebPT